Taken together, we have validated in vivo that the engineered destabilized 3’UTR of ERBB2 significantly reduced the tumor volume in a deadly drug-resistant tumor model with no abnormal blood, liver, kidney, bone, pancreas, gall bladder, and electrolyte imbalance. Here, ERBB2 is linked to neoplasm.